Is the Point Mutation in Codon 331 of the Mitochondrial ND2 Gene Associated with Alzheimer’s Disease?

  • Bernd Janetzky
  • Christoph Schmid
  • Peter Riederer
  • Heinz Reichmann
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)

Abstract

Alzheimers disease (AD) is characterized by the presence of numerous neurofibrillary tangles and neuritic plaques in the neocortex, especially in the hippocampus. Besides there is ample evidence of disturbances of energy metabolism. Biochemical analyses demonstrated reduction of pyruvate dehydrogenase activity3 and abnormalities of the respiratory chain4,5 in post mortem brain tissue from AD patients. Point mutations in mtDNA, as it was shown for some other encephalomyo-pathies and neurodegenerative disorders6 are reported in about 50% of AD patients.7 Two types of mutations, both at mtDNA position 5460 in codon 331 of the ND2 gene, are described (Figure 1): a G4A transition converting the wildtype amino acid alanine to threonine and a G4T mutation converting alanine to serine. None of the controls showed these mutations. Analyses of Petruzzella et al.2 couldn’t confirm these findings, suggesting a neutral polymorphism not specifically related with AD. We report here the use of allele specific PCR to search for mutations at nt 5460 in post mortem brain and blood of AD patients and blood and muscle tissue of patients with presumed mitochondrial encephalomyopathies.

Keywords

Mitochondrial Genome Amino Acid Alanine Control Fragment Neutral Polymorphism Wild Type Amino Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    F.-H. Lin, R. Lin, H.M. Wisniewski, Y.-W. Hwang, I. Grundke-Iqbal, H.L. Healy-Louie, and K. Iqbal, Detection of point mutations in codon 331 of mitochondria) NADH dehydrogenase subunit 2 in Alzheimer’s brains, Biochem. Biophys. Res. Commun. 182: 238–246 (1992).PubMedCrossRefGoogle Scholar
  2. 2.
    V. Petruzella, X. Chen, and E.A. Schon, Is a point mutation in the mitochondria) ND2 gene associated with Alzheimer’s disease, Biochem. Biophys. Res. Commun. 186: 491–497 (1992).CrossRefGoogle Scholar
  3. 3.
    S. Sorbi, E.D. Bird, and J.P. Blass, Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain, Ann Neurol. 13: 72–78 (1983).PubMedCrossRefGoogle Scholar
  4. 4.
    H. Reichmann, S. Flórke, G. Hebenstreit, H. Schrubar, and P. Riederer, Analyses of energy metabolism and mitochondria) genome in post-mortem brain from patients with Alzheimer’s disease, J. Neurol. 240: 377–380 (1993).PubMedCrossRefGoogle Scholar
  5. 5.
    V.D. Parker, C.M. Filley, and J.K. Parks, Cytochrome oxidase deficiency in Alzheimer’s disPAse, Neurology 40: 1302–1303 (1990).PubMedCrossRefGoogle Scholar
  6. 6.
    D.C. Wallace, Diseases of the mitochondria) DNA, Ann Rev Biochem. 61: 1175–1212 (1992).PubMedCrossRefGoogle Scholar
  7. 7.
    P. Lestienne, I. Nelson, P. Riederer, K. Jellinger, and H. Reichmann, Normal mitochondria) genome in brain from patients with Parkinson’s disease and complex I defect, J. Neurochem. 55: 1810–1812 (1990).PubMedCrossRefGoogle Scholar
  8. 8.
    S.R. Hammans, M.G. Sweeney, M. Brockington, J.A. Morgan-Hughes, and A.E. Harding, Mitochondria) encephalopathies–molecular genetic diagnosis from blood samples, Lancet. i: 1311–1313 (1991).Google Scholar
  9. 9.
    F. Sanger, S. Nicklen, and A.R. Coulson, DNA sequencing with chain-terminating inhibitors, Proc. Natl. Acad Sci USA. 74: 5463–5467 (1977).PubMedCrossRefGoogle Scholar
  10. 10.
    P. Seibel, F. Degoul, N. Romero, C. Marsac, and B. Kadenbach, Identification of point mutations by mispairing PCR as exemplified in MERRF disease, Biochem. Biophys. Res. Commun. 173: 561–565 (1990).PubMedCrossRefGoogle Scholar
  11. 11.
    F.-H. Lin, and R. Lin, A comparison of single nucleotide primer extension with mispairing PCR-RFLP in detecting a point mutation, Biochem. Biophys. Res. Commun. 189: 1202–1206 (1992).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Bernd Janetzky
    • 1
  • Christoph Schmid
    • 1
  • Peter Riederer
    • 2
  • Heinz Reichmann
    • 1
  1. 1.Institutes of NeurologyUniversity of WürzburgWürzburgGermany
  2. 2.Institutes of PsychiatryUniversity of WürzburgWürzburgGermany

Personalised recommendations